Multiple functions of CXCL12 in a syngeneic model of breast cancer

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Williams, Sharon A ^a   Harata Lee, Yuka ^a   Comerford, Iain ^a   Anderson, Robin L ^b   Smyth, Mark J ^b   McColl, Shaun R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P 15095; STROMAL CELL DERIVED FACTOR 1; CHEMOKINE RECEPTOR CXCR4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; IMMUNE RESPONSE; IN VITRO STUDY; LYMPH NODE; METASTASIS; METASTASIS POTENTIAL; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; DENDRITIC CELL; DRUG ANTAGONISM; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, SCID; RECEPTORS, CXCR4;

EID: 77957696221     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-250     Document Type: Article

References (26)

1. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996, 184:1101-1109. 10.1084/jem.184.3.1101, 2192798, 9064327.
2. Vecchi A, Massimiliano L, Ramponi S, Luini W, Bernasconi S, Bonecchi R, Allavena P, Parmentier M, Mantovani A, Sozzani S. Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J Leukoc Biol 1999, 66:489-494.
3. Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, Giladi H, Brocke S, Hanna J, Mandelboim O, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 2003, 102:1951-1958. 10.1182/blood-2002-10-3293, 12730102.
4. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
5. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767. 10.1182/blood-2005-08-3182, 16269611.
6. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348. 10.1016/j.cell.2005.02.034, 15882617.
7. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004, 23:157-167. 10.1038/sj.onc.1206910, 14712221.
8. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 Blocks Breast Cancer Metastasis. Cancer Res 2005, 65:967-971.
9. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612. 10.1158/0008-5472.CAN-04-1844, 15574767.
10. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003, 550:79-83. 10.1016/S0014-5793(03)00824-X, 12935890.
11. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD, Clark-Lewis I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. Embo J 1997, 16:6996-7007. 10.1093/emboj/16.23.6996, 1170303, 9384579.
12. Billiau A, Matthys P. Interferon-[gamma]: A historical perspective. Cytokine & Growth Factor Reviews 2009, 20:97-113.
13. Fushimi T, O'Connor TP, Crystal RG. Adenoviral Gene Transfer of Stromal Cell-Derived Factor-1 to Murine Tumors Induces the Accumulation of Dendritic Cells and Suppresses Tumor Growth. Cancer Res 2006, 66:3513-3522. 10.1158/0008-5472.CAN-05-1493, 16585175.
14. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology 2006, 16:53-65. 10.1016/j.semcancer.2005.07.005, 16168663.
15. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H. Inhibition of Breast Cancer Metastasis by Selective Synthetic Polypeptide against CXCR4. Cancer Res 2004, 64:4302-4308. 10.1158/0008-5472.CAN-03-3958, 15205345.
16. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2004, 12(1):84-9.
17. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005, 54(11):1137-42. 10.1007/s00262-005-0703-4, 15877228.
18. Dunussi-Joannopoulos K, Zuberek K, Runyon K, Hawley RG, Wong A, Erickson J, Herrmann S, Leonard JP. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood 2002, 100:1551-1558.
19. Nomura T, Hasegawa H, Kohno M, Sasaki M, Fujita S. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes. Int J Cancer 2001, 91:597-606. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1107>3.0.CO;2-J, 11267967.
20. Kabashima K, Sugita K, Shiraishi N, Tamamura H, Fujii N, Tokura Y. CXCR4 engagement promotes dendritic cell survival and maturation. Biochem Biophys Res Commun 2007, 361(4):1012-6. 10.1016/j.bbrc.2007.07.128, 17679142.
21. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001, 7:1339-1346. 10.1038/nm1201-1339, 11726975.
22. Pak AS, Ip G, Wright MA, Young MR. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res 1995, 55:885-890.
23. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A, Pfeffer U. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer 2009, 45:2579-2587. 10.1016/j.ejca.2009.06.026, 19646861.
24. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999, 17:163-170. 10.1023/A:1006689719505, 10411109.
25. Rockwell S. Effect of host age on the transplantation, growth, and radiation response of EMT6 tumors. Cancer Res 1981, 41:527-531.
26. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001, 193:661-670. 10.1084/jem.193.6.661, 2193421, 11257133.